Free Account Opening + AMC Free Demat
Loading...

Sanginita Chemicals Rights Issue 2024 vs Solara Active Pharma Sciences Rights Issue 2024

Comparision between Sanginita Chemicals Rights Issue 2024 and Solara Active Pharma Sciences Rights Issue 2024.

Rights Issue details

Find important information like Listing Exchange, Terms of payment and Entitlement Ratio for Sanginita Chemicals Rights Issue 2024 and Solara Active Pharma Sciences Rights Issue 2024. Sanginita Chemicals Rights Issue 2024 is listed on NSE while Solara Active Pharma Sciences Rights Issue 2024 is listed on BSE, NSE.

  Sanginita Chemicals Limited Solara Active Pharma Sciences Ltd
Logo Sanginita Chemicals Rights Issue 2024 Logo Solara Active Pharma Sciences Rights Issue 2024 Logo
Listing At NSE BSE, NSE
Terms of Payment

The full amount for Rights Equity Shares of Rs.18 shall be payable by the eligible shareholders at the time of making an application.

Issue Price of Rs.375/- per share is payable as Rs.131.25 per share on Application. The remaining amount will be called within 24 months from the date of allotment in the Issue or within such extended period as may be determined by the Board or Rights Issue Committee of the Company at its sole discretion from time to time.

Entitlement 1 Rights Equity Share(s) for every 2 fully paid-up Equity Shares held on Record Date 1 Rights Equity Share(s) for every 3 fully paid-up Equity Shares held on Record Date
Application Form Application Form Application Form
Letter of Offer Letter of Offer Letter of Offer
Registrar Purva Sharegistry India Pvt Ltd Cameo Corporate Services Limited
Lead Managers Fintellectual Corporate Advisors Private Limited Choice Capital Advisors Pvt Ltd

Rights Issue Size and Price

The issue size of Sanginita Chemicals Rights Issue 2024 rights issue is ₹15.54 Crores, whereas Solara Active Pharma Sciences Rights Issue 2024 rights issue size is ₹449.95 Crores.

  Sanginita Chemicals Limited Solara Active Pharma Sciences Ltd
Issue Size 86,33,850 shares 1,19,98,755 shares
Issue Size (Amount) ₹15.54 Crores ₹449.95 Crores
Issue Price ₹18 per share ₹375 per share
Face Value ₹10 per share ₹10 per share

Rights Issue Timetable

Find all the important dates related to the rights issue. The record date of Sanginita Chemicals Rights Issue 2024 is May 07, 2024 while record date of Solara Active Pharma Sciences Rights Issue 2024 is May 15, 2024.

  Sanginita Chemicals Limited Solara Active Pharma Sciences Ltd
Record Date May 07, 2024 May 15, 2024
Credit of Rights Entitlements May 27, 2024
Bid/Offer Opens On May 15, 2024 May 28, 2024
Renunciation of Rights Entitlements May 21, 2024 Jun 05, 2024
Bid/Offer Closes On May 27, 2024 Jun 11, 2024
Deemed Date of Allotment May 30, 2024 Jun 19, 2024
Credit Date Jun 05, 2024 Jun 19, 2024
Listing Date May 06, 2024 Jun 20, 2024

Financials details

Comparison of Sanginita Chemicals Rights Issue 2024 and Solara Active Pharma Sciences Rights Issue 2024 financial data, including total revenue, PAT, and net worth. The table below also includes a list of all relevant documents like the Application Form and Letter of Offer. Related Parties like Lead Manager and Registrar are also mentioned in this section.

  Sanginita Chemicals Limited Solara Active Pharma Sciences Ltd
Financial

Sanginita Chemicals Limited Financial Information (Restated Standalone)

Sanginita Chemicals Limited's revenue decreased by -24.85% and profit after tax (PAT) rose by 19.57% between the financial year ending with March 31, 2023 and March 31, 2022.

Period Ended31 Mar 202331 Mar 202231 Mar 2021
Assets79.5079.2070.12
Revenue149.13198.44165.02
Profit After Tax0.420.350.76
Amount in ₹ Crore

Solara Active Pharma Sciences Ltd Financial Information (Restated Consolidated)

Solara Active Pharma Sciences Ltd's revenue increased by 13.82% and profit after tax (PAT) rose by 61.85% between the financial year ending with March 31, 2023 and March 31, 2022.

Period Ended31 Mar 202331 Mar 202231 Mar 2021
Assets28.9929.4526.14
Revenue14.6612.8816.46
Profit After Tax-0.22-0.582.21
Amount in ₹ Crore

Comments

Add a public comment...